Synaptic dysfunction represents an early pathological event that precedes neurodegeneration in Alzheimer’s disease (AD), even though the molecular mechanisms that underlie synaptic dysfunction remain to be completely understood. Nonetheless, in vivo synaptic biomarkers are highly relevant as they have the potential to reveal early-stage changes and to track target engagement of specific disease-modifying strategies.
Cerebrospinal fluid cyclase-associated protein 2 is increased in Alzheimer's disease and correlates with tau pathology
Benussi, Alberto;
2025-01-01
Abstract
Synaptic dysfunction represents an early pathological event that precedes neurodegeneration in Alzheimer’s disease (AD), even though the molecular mechanisms that underlie synaptic dysfunction remain to be completely understood. Nonetheless, in vivo synaptic biomarkers are highly relevant as they have the potential to reveal early-stage changes and to track target engagement of specific disease-modifying strategies.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
39819731.pdf
accesso aperto
Tipologia:
Documento in Versione Editoriale
Licenza:
Creative commons
Dimensione
677.28 kB
Formato
Adobe PDF
|
677.28 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
